Related references
Note: Only part of the references are listed.Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy A Clinical Trial
Stephen B. Heitner et al.
ANNALS OF INTERNAL MEDICINE (2019)
Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy
Sarah R. Clippinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Force Generation via β-Cardiac Myosin, Titin, and α-Actinin Drives Cardiac Sarcomere Assembly from Cell-Matrix Adhesions
Anant Chopra et al.
DEVELOPMENTAL CELL (2018)
Sarcomeric perturbations of myosin motors lead to dilated cardiomyopathy in genetically modified MYL2 mice
Chen-Ching Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin
John A. Rohde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle
Petr G. Vikhorev et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers
Robert L. Anderson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
Julien Robert-Paganin et al.
NATURE COMMUNICATIONS (2018)
A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle
Raja F. Kawas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Effects of myosin variants on interacting heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes
Lorenzo Alamo et al.
ELIFE (2017)
Insights and Challenges of Multi-Scale Modeling of Sarcomere Mechanics in cTn and Tm DCM Mutants-Genotype to Cellular Phenotype
Sukriti Dewan et al.
FRONTIERS IN PHYSIOLOGY (2017)
A Cardiomyopathy Mutation in the Myosin Essential Light Chain Alters Actomyosin Structure
Piyali Guhathakurta et al.
BIOPHYSICAL JOURNAL (2017)
Myosin light chain phosphorylation, novel targets to repair a broken heart?
Danuta Szczesna-Cordary et al.
CARDIOVASCULAR RESEARCH (2016)
A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy
Jennifer Davis et al.
CELL (2016)
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases
Yigal M. Pinto et al.
EUROPEAN HEART JOURNAL (2016)
Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin
James A. Spudich et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2016)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink et al.
LANCET (2016)
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Eric M. Green et al.
SCIENCE (2016)
How Myosin Generates Force on Actin Filaments
Anne Houdusse et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin
Arjun S. Adhikari et al.
CELL REPORTS (2016)
A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy
Joshua A. Stern et al.
PLOS ONE (2016)
Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under load
Anastasia Karabina et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2015)
Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine beta-Cardiac Myosin
Yingying Liu et al.
BIOCHEMISTRY (2015)
Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain
Wenrui Huang et al.
FEBS JOURNAL (2015)
Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations
Wenrui Huang et al.
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY (2015)
Targeting the sarcomere to correct muscle function
Peter M. Hwang et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice
Chen-Ching Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy
John T. Hinson et al.
SCIENCE (2015)
Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity
Donald A. Winkelmann et al.
NATURE COMMUNICATIONS (2015)
Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function
Matthew J. Birket et al.
CELL REPORTS (2015)
Ensemble Force Changes that Result from Human Cardiac Myosin Mutations and a Small-Molecule Effector
Tural Aksel et al.
CELL REPORTS (2015)
Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases
James A. Spudich
BIOPHYSICAL JOURNAL (2014)
Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy
Ranganath Mamidi et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2014)
Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy
E. Rosalie Witjas-Paalberends et al.
CARDIOVASCULAR RESEARCH (2013)
Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function
Ruth F. Sommese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Understanding Cardiomyopathy Phenotypes Based on the Functional Impact of Mutations in the Myosin Motor
Jeffrey R. Moore et al.
CIRCULATION RESEARCH (2012)
Truncations of Titin Causing Dilated Cardiomyopathy
Daniel S. Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G. F. Cleland et al.
LANCET (2011)
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink et al.
LANCET (2011)
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik et al.
SCIENCE (2011)
Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex
Bradley M. Palmer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils
Alexandra Belus et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function
Joachim P. Schmitt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations
NR Alpert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties
DI Keller et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium
BM Palmer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy
MJ Tyska et al.
CIRCULATION RESEARCH (2000)
Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy
AJ Marian
LANCET (2000)
Share Paper
